Aldeyra Therapeutics has disclosed positive results from the first of multiple Phase 3 studies of a new type of inflammation-fighting medicine the Lexington, MA, company has been testing in a variety of conditions.

The study Aldeyra (NASDAQ: ALDX) reports on this morning is a Phase 3 trial called “Alleviate,” which tested its drug reproxalap against a placebo eye drop in 318 patients with seasonal allergic conjunctivitis, a chronic condition that causes itchy and watery eyes.

Aldeyra said both tested doses of reproxalap, an eye drop, led to a statistically significant improvement on a scoring system that measures the severity of… Read more »